Aliases & Classifications for Retinal Ischemia

MalaCards integrated aliases for Retinal Ischemia:

Name: Retinal Ischemia 38 12 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:12510
ICD10 33 H35.82
ICD9CM 35 362.84
SNOMED-CT 64 193427006 26468004
UMLS 69 C0162291

Summaries for Retinal Ischemia

MalaCards based summary : Retinal Ischemia is related to exudative vitreoretinopathy 3 and mini stroke. An important gene associated with Retinal Ischemia is HIF1A (Hypoxia Inducible Factor 1 Alpha Subunit), and among its related pathways/superpathways are PEDF Induced Signaling and PAK Pathway. The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include endothelial, bone and eye, and related phenotypes are Increased Nanog expression and cellular

Related Diseases for Retinal Ischemia

Diseases related to Retinal Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
id Related Disease Score Top Affiliating Genes
1 exudative vitreoretinopathy 3 10.8
2 mini stroke 10.8
3 exudative vitreoretinopathy 4 10.8
4 transient cerebral ischemia 10.8
5 exudative vitreoretinopathy 1 10.8
6 exudative vitreoretinopathy 2, x-linked 10.8
7 retinitis 10.8
8 ischemia 10.8
9 low compliance bladder 10.4 CAT TNF
10 iridogoniodysgenesis and skeletal anomalies 10.4 HIF1A VEGFA
11 akaba hayasaka syndrome 10.3 CXCL12 TNF
12 cutaneous leishmaniasis 10.3 TNF VEGFA
13 tracheal lymphoma 10.3 CASP3 CAT
14 large intestine adenoma 10.2 CASP3 HIF1A VEGFA
15 myoclonic encephalopathy of infants 10.2 CAT SOD1
16 ladd syndrome 10.2 BAX CASP3 HIF1A
17 mucinous tubular and spindle renal cell carcinoma 10.2 HIF1A SETD2 VEGFA
18 villous adenoma 10.1 CASP3 HIF1A VEGFA
19 central nervous system vasculitis 10.1 CXCL12 HIF1A VEGFA
20 neuronitis 10.1
21 gallbladder cancer 10.1 CASP3 TNF VEGFA
22 endotheliitis 10.1
23 segmental odontomaxillary dysplasia 10.0 TNF VEGFA
24 hartnup disorder 10.0 CASP3 HIF1A VEGFA
25 asbestosis 9.9 CAT SOD1 TNF
26 measles 9.9 BAX CAT VEGFA
27 renal fibrosis 9.9 CXCL12 HIF1A TNF VEGFA
28 retinal vein occlusion 9.8
29 choroiditis 9.8
30 mature teratoma 9.8 BAX BCL2
31 upper gum cancer 9.8 SOD1 TNF
32 retinal artery occlusion 9.8
33 central retinal artery occlusion 9.8
34 neurofibromatosis, type 1 9.8
35 early-onset zonular cataract 9.8 SOD1 TNF VEGFA
36 lopes-maciel-rodan syndrome 9.8 CASP2 CASP3 SETD2 SOD1
37 cpt deficiency, hepatic, type ia 9.8 CASP3 CXCL12 TNF VEGFA
38 pulmonary hypertension 9.7 BAX BCL2 TNF
39 temporal arteritis 9.7
40 cataract 9.7
41 ocular hypertension 9.7
42 neovascular glaucoma 9.7
43 hypoxia 9.7
44 cerebritis 9.7
45 primary malignant melanoma of the cervix 9.7 BCL2 CXCL12
46 nail disorder, nonsyndromic congenital, 3, 9.7 BAX CASP3 HIF1A VEGFA
47 calciphylaxis 9.6 KNG1 SOD1 VEGFA
48 ovarian brenner tumor 9.6 CXCL12 HIF1A SETD2 TNF VEGFA
49 sparse hair ptosis mental retardation 9.6 BCL2 TNF VEGFA
50 hydromyelia 9.6 BCL2 SOD1

Comorbidity relations with Retinal Ischemia via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Retinal Ischemia:



Diseases related to Retinal Ischemia

Symptoms & Phenotypes for Retinal Ischemia

GenomeRNAi Phenotypes related to Retinal Ischemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased Nanog expression GR00371-A-1 9.9 CASP2 PCNA SETD2 VEGFA
2 Increased Nanog expression GR00371-A-2 9.9 SETD2 VEGFA
3 Increased Nanog expression GR00371-A-4 9.9 SETD2 VEGFA
4 Increased Nanog expression GR00371-A-5 9.9 CASP2 SETD2 VEGFA
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 TNF BAX BCL2 CASP3 HIF1A PCNA
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 TNF BAX BCL2 CASP3 HIF1A PCNA
7 Increased cell death HMECs cells GR00103-A-0 9.72 CASP2 CASP3 CAT HIF1A PCNA
8 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.65 CAT PCNA TNF CASP2 CASP3
9 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.35 BAX BCL2 HIF1A PCNA SOD1

MGI Mouse Phenotypes related to Retinal Ischemia:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.29 BAX BCL2 CASP2 CASP3 CAT CXCL12
2 hematopoietic system MP:0005397 10.27 BAX BCL2 CASP2 CASP3 CXCL12 HIF1A
3 growth/size/body region MP:0005378 10.25 BAX BCL2 CASP3 HIF1A HSPB1 KNG1
4 mortality/aging MP:0010768 10.21 SETD2 SOD1 TNF VEGFA BAX BCL2
5 immune system MP:0005387 10.2 BCL2 CASP2 CASP3 CXCL12 HIF1A HSPB1
6 endocrine/exocrine gland MP:0005379 10.18 BAX BCL2 CASP2 CASP3 HIF1A PCNA
7 homeostasis/metabolism MP:0005376 10.18 BAX BCL2 CASP3 CAT HIF1A HSPB1
8 cardiovascular system MP:0005385 10.16 BCL2 CASP3 CXCL12 HIF1A SETD2 SOD1
9 nervous system MP:0003631 10.02 BAX BCL2 CASP2 CASP3 CXCL12 HIF1A
10 craniofacial MP:0005382 10.01 BCL2 CASP3 HIF1A SETD2 TNF VEGFA
11 muscle MP:0005369 10.01 BAX BCL2 CASP3 CXCL12 HIF1A SOD1
12 neoplasm MP:0002006 9.91 CAT HIF1A SOD1 TNF VEGFA BAX
13 reproductive system MP:0005389 9.81 CASP2 CASP3 CXCL12 PCNA SOD1 TNF
14 no phenotypic analysis MP:0003012 9.73 CASP3 CXCL12 HSPB1 PCNA TNF VEGFA
15 respiratory system MP:0005388 9.43 BAX BCL2 CASP3 HIF1A TNF VEGFA
16 vision/eye MP:0005391 9.23 HIF1A SETD2 SOD1 TNF VEGFA BAX

Drugs & Therapeutics for Retinal Ischemia

Drugs for Retinal Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
2
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2 347396-82-1 459903
3
Choline Approved, Nutraceutical Phase 4 62-49-7 305
4 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
5 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Cytidine Diphosphate Choline Phase 4
7 Nootropic Agents Phase 4
8 Antibodies Phase 4
9 Immunoglobulins Phase 4
10
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 50-24-8 5755
12
Eplerenone Approved Phase 2, Phase 3 107724-20-9 150310 443872
13
Spironolactone Approved Phase 2, Phase 3 1952-01-7, 52-01-7 5833
14
Irbesartan Approved, Investigational Phase 3 138402-11-6 3749
15
Triamcinolone Approved, Vet_approved Phase 3,Phase 2 124-94-7 31307
16
Vorapaxar Approved Phase 3 618385-01-6
17
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
18
Dalteparin Approved Phase 3 9005-49-6
19
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
20
Clopidogrel Approved, Nutraceutical Phase 3 120202-66-6, 113665-84-2 60606
21
Angiotensin II Investigational Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
22 Antiemetics Phase 3,Phase 1,Phase 2
23 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
24 Antineoplastic Agents, Hormonal Phase 3
25 Autonomic Agents Phase 3,Phase 1,Phase 2
26 Gastrointestinal Agents Phase 3,Phase 1,Phase 2
27 glucocorticoids Phase 3,Phase 1,Phase 2
28 Hormone Antagonists Phase 3,Phase 2,Phase 1
29 Hormones Phase 3,Phase 2,Phase 1
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
31 Methylprednisolone acetate Phase 3,Phase 1,Phase 2
32 Methylprednisolone Hemisuccinate Phase 3,Phase 1,Phase 2
33 Neuroprotective Agents Phase 3,Phase 1,Phase 2
34 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
35 Prednisolone acetate Phase 3,Phase 1,Phase 2
36 Prednisolone hemisuccinate Phase 3,Phase 1,Phase 2
37 Prednisolone phosphate Phase 3,Phase 1,Phase 2
38 Protective Agents Phase 3,Phase 1,Phase 2
39 diuretics Phase 2, Phase 3
40 Diuretics, Potassium Sparing Phase 2, Phase 3
41 Mineralocorticoid Receptor Antagonists Phase 2, Phase 3
42 Mineralocorticoids Phase 2, Phase 3
43 Natriuretic Agents Phase 2, Phase 3
44 Endothelial Growth Factors Phase 3,Phase 1,Phase 2
45 Mitogens Phase 3,Phase 1,Phase 2
46 Angiotensin II Type 1 Receptor Blockers Phase 3
47 Angiotensin Receptor Antagonists Phase 3
48 Angiotensinogen Phase 3
49 Antihypertensive Agents Phase 3
50 Immunosuppressive Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 79)

id Name Status NCT ID Phase Drugs
1 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
2 Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial Completed NCT02299336 Phase 4 Aflibercept
3 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Completed NCT01710839 Phase 4 0.5mg Ranibizumab
4 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
5 Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
6 Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Completed NCT00557232 Phase 4 bevacizumab
7 Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases Completed NCT00404729 Phase 4 Cytidine-5’-diphosphocholine (Citicoline)
8 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Recruiting NCT02432547 Phase 4 Aflibercept
9 Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion Recruiting NCT02478515 Phase 4 Ranibizumab
10 Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa Recruiting NCT02554747 Phase 4
11 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Active, not recruiting NCT02503540 Phase 4 Aflibercept
12 Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA Not yet recruiting NCT03246152 Phase 4 Bevacizumab
13 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Not yet recruiting NCT02522897 Phase 4 Ranibizumab
14 Outcomes of Steroid and Oxygen Therapy Versus Placebo Therapy in Non-arteritic Anterior Ischemic Optic Neuropathy Unknown status NCT02439866 Phase 3 placebo;Intravenous methylprednisolone;normobaric oxygen with face mask
15 A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
16 Central Vein Occlusion Study (CVOS) Completed NCT00000131 Phase 3
17 Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion Completed NCT02033031 Phase 3 Lucentis intravitreal injection;Avastin intravitreal injection
18 Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia Completed NCT00152698 Phase 3 Irbesartan
19 Combined Triple Procedure in Retinal Vein Occlusion (RVO) Completed NCT00805064 Phase 3 triamcinolone and bevacizumab
20 Intravitreal Bevacizumab for Diabetic Retinopathy Completed NCT00600262 Phase 2, Phase 3 intravitreal bevacizumab
21 Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183) Completed NCT00617123 Phase 3 Vorapaxar 2.5 mg;Placebo
22 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial Recruiting NCT00991029 Phase 3 Clopidogrel;placebo
23 Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Recruiting NCT02341560 Phase 2, Phase 3 QPI-1007 Injection - single low dose;QPI-1007 Injection - single high dose;QPI-1007 Injection - multiple low dose;QPI-1007 Injection - multiple high dose
24 Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG Not yet recruiting NCT02947867 Phase 2, Phase 3 aganirsen
25 Parnaparin vs Aspirin in the Treatment of Retinal Vein Occlusion Terminated NCT00732927 Phase 3 parnaparin;aspirin
26 Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients Unknown status NCT02405741 Phase 2
27 Comparison of Two Laser Therapy Methods for PDR Unknown status NCT01232179 Phase 2
28 Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease Completed NCT00841373 Phase 1, Phase 2
29 Traumatic Optic Neuropathy Treatment Trial (TONTT) Completed NCT01783847 Phase 1, Phase 2 Recombinant human erythropoietin (EPO)
30 A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow Completed NCT00569621 Phase 2 Moxaverine;physiological saline
31 Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion Completed NCT00815360 Phase 2 intravitreal injection of ranibizumab;intravitreal injection of triamcinolone acetonide
32 Effects of Moxaverine and Placebo on Ocular Blood Flow Completed NCT00709423 Phase 2 Moxaverine;Moxaverin 150mg;NaCl
33 Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. Recruiting NCT02222610 Phase 2 0.5 mg ranibizumab
34 Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment. Recruiting NCT02957760 Phase 2 Hydroxycarbamid
35 Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy. Recruiting NCT02151695 Phase 2 Aflibercept intravitreal injections
36 Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) Active, not recruiting NCT01552408 Phase 1, Phase 2 0.3 mg ranibizumab
37 Intraocular Pressure During Prone Spinal Surgery Terminated NCT00176722 Phase 2
38 Lucentis for New Onset Neovascular Glaucoma Withdrawn NCT00727038 Phase 1, Phase 2 Ranibizumab (Lucentis)
39 A Phase I Clinical Trial of DARC Unknown status NCT02394613 Phase 1 ANX776
40 Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion Completed NCT00406471 Phase 1 Ranibizumab (Lucentis)
41 NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement Completed NCT01411657 Phase 1 NT-501 CNTF Implant
42 Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients Completed NCT01064505 Phase 1 QPI-1007 at various doses
43 Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) Terminated NCT01225146 Phase 1 ranibizumab
44 Study on the Oxygen Saturation in Pulsating and Non-pulsating Central Retinal Veins Unknown status NCT01794442
45 OCT in Retinal Vein Occlusions Unknown status NCT01992575
46 Optical Coherence Tomography (OCT) in Retinal Vasculitis Unknown status NCT01998464
47 Prophylactic Laser Photocoagulation and Vitrectomy for Acute Retinal Necrosis Unknown status NCT02222857
48 Diabetes PRP and OCT Unknown status NCT01928550
49 Retinal Oximtery Following Treatment for Diabetic Maculopathy Unknown status NCT01549132
50 Pilot Study of OCT Versus Fluorescein Angiography in DME Unknown status NCT01876914

Search NIH Clinical Center for Retinal Ischemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Retinal Ischemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Retinal Ischemia:
Bone marrow-derived stem cells for retinal diseases
Embryonic/Adult Cultured Cells Related to Retinal Ischemia:
Bone marrow-derived mononuclear cells (family) PMIDs: 23049424 21225138 19347139 23000646

Genetic Tests for Retinal Ischemia

Anatomical Context for Retinal Ischemia

MalaCards organs/tissues related to Retinal Ischemia:

39
Endothelial, Bone, Eye, Retina, Bone Marrow, Brain, Neutrophil

Publications for Retinal Ischemia

Articles related to Retinal Ischemia:

(show top 50) (show all 305)
id Title Authors Year
1
OCT Angiography: Assessment of Retinal Ischemia in Susac's Syndrome. ( 28613358 )
2017
2
Protective Effect of Intravitreal Administration of Exosomes Derived from Mesenchymal Stem Cells on Retinal Ischemia. ( 28636406 )
2017
3
Neuroprotective effects of a novel peptide, FK18, under oxygen-glucose deprivation in SH-SY5Y cells and retinal ischemia in ratsA viaA the Akt pathway. ( 28257830 )
2017
4
Transplantation of lineage-negative stem cells in pterygopalatine artery ligation induced retinal ischemia-reperfusion injury in mice. ( 28210901 )
2017
5
Overexpression of Heme Oxygenase-1 in Mesenchymal Stem Cells Augments Their Protection on Retinal Cells In Vitro and Attenuates Retinal Ischemia/Reperfusion Injury In Vivo against Oxidative Stress. ( 28255307 )
2017
6
Optic Nerve Degeneration after Retinal Ischemia/Reperfusion in a Rodent Model. ( 28878627 )
2017
7
Myeloid differentiation protein 2-dependent mechanisms in retinal ischemia-reperfusion injury. ( 28063877 )
2017
8
Response by Golsari and Thomalla to Letter Regarding Article, "Silent Brain Infarctions and Leukoaraiosis in Patients With Retinal Ischemia: A Prospective Single-Center Observational Study". ( 28626060 )
2017
9
Dexmedetomidine preconditioning protects against retinal ischemia/reperfusion injury and inhibits inflammation response via toll-like receptor 4 (TLR4) pathway. ( 28724211 )
2017
10
Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1I+ and VEGF via inhibition of RBP2 and PKM2. ( 28709426 )
2017
11
Reversibility of retinal ischemia due to central retinal artery occlusion by hyperbaric oxygen. ( 28096655 )
2017
12
Silent Brain Infarctions and Leukoaraiosis in Patients With Retinal Ischemia: A Prospective Single-Center Observational Study. ( 28386036 )
2017
13
Norrin treatment improves ganglion cell survival in an oxygen-induced retinopathy model of retinal ischemia. ( 28823941 )
2017
14
Passage through the Ocular Barriers and Beneficial Effects in Retinal Ischemia of Topical Application of PACAP1-38 in Rodents. ( 28335564 )
2017
15
Bone-marrow mesenchymal stem-cell administration significantly improves outcome after retinal ischemia in rats. ( 28523456 )
2017
16
Thrombolyic and Vasodilator Treatment in a Patient With Prolonged Retinal Ischemia. ( 28471897 )
2017
17
Curcumin protects against hypertension aggravated retinal ischemia/reperfusion in a rat stroke model. ( 28678631 )
2017
18
Letter by Kawada Regarding Article, "Silent Brain Infarctions and Leukoaraiosis in Patients With Retinal Ischemia: A Prospective Single-Center Observational Study". ( 28626051 )
2017
19
Utility of optical coherence tomography in the evaluation of monocular visual loss related to retinal ischemia. ( 26765759 )
2016
20
Refractory acute angle-closure glaucoma with retinal ischemia: January consultation #1. ( 26948794 )
2016
21
Involvement of microRNA-181a and Bim in a rat model of retinal ischemia-reperfusion injury. ( 26949607 )
2016
22
Peripheral retinal ischemia in a young Indian woman with neurofibromatosis type 1. ( 26949362 )
2016
23
Methane attenuates retinal ischemia/reperfusion injury via anti-oxidative and anti-apoptotic pathways. ( 27208496 )
2016
24
Lower Hemoglobin Concentration Is Associated with Retinal Ischemia and the Severity of Diabetic Retinopathy in Type 2 Diabetes. ( 27200379 )
2016
25
A Mouse Model of Retinal Ischemia-Reperfusion Injury Through Elevation of Intraocular Pressure. ( 27501124 )
2016
26
Calpain-1 and calpain-2 play opposite roles in retinal ganglion cell degeneration induced by retinal ischemia/reperfusion injury. ( 27185592 )
2016
27
Functional and Structural Evaluation of Sildenafil in a Rat Model of Acute Retinal Ischemia/Reperfusion Injury. ( 27421045 )
2016
28
Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase. ( 27617027 )
2016
29
Cryopreserved Mesenchymal Stromal Cells Maintain Potency in a Retinal Ischemia/Reperfusion Injury Model: Toward an off-the-shelf Therapy. ( 27212469 )
2016
30
C1q propagates microglial activation and neurodegeneration in the visual axis following retinal ischemia/reperfusion injury. ( 27008854 )
2016
31
Neuroprotective impact of prothymosin alpha-derived hexapeptide against retinal ischemia-reperfusion. ( 26779836 )
2016
32
Cannabinoid receptors and TRPA1 on neuroprotection in a model of retinal ischemia. ( 27876485 )
2016
33
Astaxanthin Protects Against Retinal Damage: Evidence from In Vivo and In Vitro Retinal Ischemia and Reperfusion Models. ( 27158842 )
2016
34
Cellular Stress Response and Immune Signaling in Retinal Ischemia-Reperfusion Injury. ( 27822213 )
2016
35
Hypoxic-Preconditioned Bone Marrow Stem Cell Medium Significantly Improves Outcome After Retinal Ischemia in Rats. ( 27367588 )
2016
36
Postconditioning with inhaled hydrogen promotes survival of retinal ganglion cells in a rat model of retinal ischemia/reperfusion injury. ( 26705611 )
2016
37
Inhibiting Matrix Metalloproteinase 3 Ameliorates Neuronal Loss in the Ganglion Cell Layer of Rats in Retinal Ischemia/Reperfusion. ( 26830289 )
2016
38
Pre-treatment with vinpocetine protects against retinal ischemia. ( 27899287 )
2016
39
The protective effect of prophylactic ozone administration against retinal ischemia-reperfusion injury. ( 27028056 )
2016
40
Protective effect of etanercept, an inhibitor of tumor necrosis factor-I+, in a rat model of retinal ischemia. ( 27259948 )
2016
41
Peripheral Retinal Ischemia, Neovascularization, and Choroidal Infarction in Wyburn-Mason Syndrome. ( 25906291 )
2015
42
Structural and functional changes in retinal vasculature induced by retinal ischemia-reperfusion in rats. ( 25728136 )
2015
43
Neuroprotective effect of water-dispersible hesperetin in retinal ischemia reperfusion injury. ( 26407617 )
2015
44
Modeling transient retinal ischemia in mouse by ligation of pterygopalatine artery. ( 26526209 )
2015
45
Nerve growth factor protects retinal ganglion cells against injury induced by retinal ischemia-reperfusion in rats. ( 25707536 )
2015
46
VINPOCETINE MODULATES METABOLIC ACTIVITY AND FUNCTION DURING RETINAL ISCHEMIA. ( 25696811 )
2015
47
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion. ( 26689280 )
2015
48
Effects of curcumin on interleukin-23 and interleukin-17 expression in rat retina after retinal ischemia-reperfusion injury. ( 26464670 )
2015
49
Upregulation of Homer1a Promoted Retinal Ganglion Cell Survival After Retinal Ischemia and Reperfusion via Interacting with Erk Pathway. ( 25924704 )
2015
50
Comparison of pre-treatment and post-treatment use of selenium in retinal ischemia reperfusion injury. ( 25938038 )
2015

Variations for Retinal Ischemia

Expression for Retinal Ischemia

Search GEO for disease gene expression data for Retinal Ischemia.

Pathways for Retinal Ischemia

Pathways related to Retinal Ischemia according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 BAX BCL2 CASP2 CASP3 CXCL12 TNF
2
Show member pathways
13.23 BAX BCL2 CASP2 CASP3 CXCL12 TNF
3
Show member pathways
12.81 BAX BCL2 CASP2 CASP3 TNF
4
Show member pathways
12.73 BAX BCL2 CASP3 HIF1A VEGFA
5
Show member pathways
12.66 BAX BCL2 CASP2 CASP3 HSPB1 TNF
6 12.62 BAX BCL2 CASP3 TNF VEGFA
7
Show member pathways
12.55 BCL2 CASP2 CASP3 TNF VEGFA
8 12.48 BAX BCL2 CASP3 CXCL12 HIF1A VEGFA
9 12.24 CASP3 HIF1A TNF VEGFA
10 12.16 BAX BCL2 CASP2 CASP3
11 12.15 BAX BCL2 CASP3 TNF
12 12.09 BAX CASP3 TNF VEGFA
13 12.07 CASP3 HIF1A TNF VEGFA
14 12.04 BCL2 CASP2 CASP3
15 12.04 BAX BCL2 CASP3 VEGFA
16
Show member pathways
12.04 BAX BCL2 CASP2 CASP3 HIF1A
17 12.03 BCL2 TNF VEGFA
18 12.01 BAX BCL2 PCNA
19 12 BAX BCL2 PCNA
20
Show member pathways
11.97 BAX BCL2 CASP3
21 11.95 BAX BCL2 TNF
22 11.93 BAX BCL2 CAT
23
Show member pathways
11.89 BAX BCL2 CASP2 CASP3 HSPB1 TNF
24 11.87 BCL2 HIF1A TNF VEGFA
25 11.86 BCL2 HIF1A VEGFA
26 11.84 CASP3 HSPB1 TNF
27 11.83 BCL2 CXCL12 TNF
28
Show member pathways
11.81 HIF1A HSPB1 VEGFA
29
Show member pathways
11.81 BAX BCL2 CASP2 CASP3 TNF
30 11.8 CXCL12 TNF VEGFA
31 11.78 BAX BCL2 CASP3
32
Show member pathways
11.76 BAX CASP3 CXCL12
33 11.69 BAX BCL2 CASP3
34
Show member pathways
11.66 BAX BCL2 CASP2 CASP3
35 11.64 CASP3 HIF1A SOD1
36 11.63 CXCL12 HIF1A VEGFA
37 11.49 CASP3 HIF1A VEGFA
38 11.49 BAX BCL2 TNF
39 11.42 BAX BCL2 CASP3
40 11.4 BAX BCL2 TNF
41 11.35 BAX BCL2 CASP3 TNF VEGFA
42 11.28 BAX HIF1A VEGFA
43 11.22 BAX CASP3 KNG1
44
Show member pathways
11.16 BAX BCL2 CASP3 CAT SOD1 TNF
45 11.15 BAX BCL2 CXCL12 TNF
47
Show member pathways
11.06 BAX BCL2
48 11.06 BAX BCL2 CASP3 TNF
49 11.03 BAX BCL2 CASP3
50 10.91 BAX BCL2 TNF

GO Terms for Retinal Ischemia

Cellular components related to Retinal Ischemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 CAT CXCL12 HSPB1 KNG1 SOD1 TNF
2 pore complex GO:0046930 8.96 BAX BCL2
3 axon cytoplasm GO:1904115 8.8 HIF1A HSPB1 SOD1

Biological processes related to Retinal Ischemia according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
id Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.89 KNG1 SOD1 VEGFA
2 positive regulation of angiogenesis GO:0045766 9.89 HIF1A HSPB1 VEGFA
3 response to virus GO:0009615 9.88 CXCL12 HSPB1 TNF
4 negative regulation of neuron apoptotic process GO:0043524 9.88 BAX BCL2 HIF1A SOD1
5 cellular response to hypoxia GO:0071456 9.87 BCL2 HIF1A VEGFA
6 response to toxic substance GO:0009636 9.86 BAX BCL2 CAT
7 response to estradiol GO:0032355 9.86 CASP3 CAT PCNA
8 response to oxidative stress GO:0006979 9.86 BCL2 CAT PCNA SOD1
9 response to organic substance GO:0010033 9.85 CASP3 SOD1 TNF
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.85 BCL2 TNF VEGFA
11 positive regulation of apoptotic process GO:0043065 9.85 BAX CASP2 CASP3 KNG1 SOD1 TNF
12 response to glucocorticoid GO:0051384 9.83 BCL2 CASP3 TNF
13 positive regulation of endothelial cell proliferation GO:0001938 9.82 CXCL12 HIF1A VEGFA
14 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.81 BAX CASP2 PCNA
15 kidney development GO:0001822 9.81 BAX BCL2 CAT VEGFA
16 response to hypoxia GO:0001666 9.8 CASP3 CAT CXCL12 HIF1A VEGFA
17 positive regulation of cell adhesion GO:0045785 9.79 CXCL12 TNF VEGFA
18 positive regulation of neuron apoptotic process GO:0043525 9.79 BAX CASP2 CASP3
19 response to radiation GO:0009314 9.77 BCL2 CAT CXCL12
20 neuron apoptotic process GO:0051402 9.77 BAX BCL2 CASP3
21 cellular response to organic substance GO:0071310 9.76 BAX BCL2 CASP3
22 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.76 BAX CASP2 CASP3 TNF
23 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.74 BAX BCL2 TNF
24 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.73 HSPB1 VEGFA
25 apoptotic signaling pathway GO:0097190 9.73 BAX CASP2 CASP3 TNF
26 release of cytochrome c from mitochondria GO:0001836 9.72 BAX BCL2
27 negative regulation of ossification GO:0030279 9.72 BCL2 HIF1A
28 positive regulation of neuroblast proliferation GO:0002052 9.72 HIF1A VEGFA
29 muscle cell cellular homeostasis GO:0046716 9.72 HIF1A SOD1
30 regulation of mitochondrial membrane potential GO:0051881 9.72 BAX BCL2 SOD1
31 positive regulation of chemokine production GO:0032722 9.71 HIF1A TNF
32 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.71 HIF1A VEGFA
33 digestive tract morphogenesis GO:0048546 9.7 BCL2 HIF1A
34 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.7 BAX BCL2
35 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.69 HSPB1 TNF
36 induction of positive chemotaxis GO:0050930 9.69 CXCL12 VEGFA
37 growth GO:0040007 9.68 BCL2 VEGFA
38 response to reactive oxygen species GO:0000302 9.68 CAT SOD1
39 myeloid cell homeostasis GO:0002262 9.67 BAX SOD1
40 regulation of protein heterodimerization activity GO:0043497 9.67 BAX BCL2
41 B cell homeostasis GO:0001782 9.67 BAX BCL2 CASP3
42 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 9.66 BAX CASP3
43 response to salt stress GO:0009651 9.66 BAX TNF
44 ectopic germ cell programmed cell death GO:0035234 9.65 BAX CASP2
45 negative regulation of apoptotic signaling pathway GO:2001234 9.65 BAX BCL2 HSPB1
46 regulation of protein homodimerization activity GO:0043496 9.64 BAX BCL2
47 positive regulation of axon extension involved in axon guidance GO:0048842 9.64 CXCL12 VEGFA
48 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.63 HSPB1 VEGFA
49 leukocyte homeostasis GO:0001776 9.62 BAX BCL2
50 response to hydrogen peroxide GO:0042542 9.62 BCL2 CASP3 CAT SOD1

Molecular functions related to Retinal Ischemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.63 BAX BCL2 CAT HSPB1 SOD1 VEGFA
2 protease binding GO:0002020 9.61 BCL2 CASP3 TNF
3 channel activity GO:0015267 9.4 BAX BCL2
4 cysteine-type endopeptidase activity involved in execution phase of apoptosis GO:0097200 9.37 CASP2 CASP3
5 enzyme binding GO:0019899 9.35 CASP2 CAT HIF1A PCNA SOD1
6 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 9.32 CASP2 CASP3
7 BH3 domain binding GO:0051434 9.26 BAX BCL2
8 identical protein binding GO:0042802 9.23 BAX BCL2 CASP2 HSPB1 PCNA SOD1
9 protein binding GO:0005515 10.23 BAX BCL2 CASP2 CASP3 HIF1A HSPB1

Sources for Retinal Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....